Delayed Adverse Events in Phase I Trials of Molecularly Targeted and Cytotoxic Agents

Oncotarget - United States
doi 10.18632/oncotarget.26104
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?

British Journal of Cancer
Cancer ResearchOncology
2009English

Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination

Clinical Cancer Research
Cancer ResearchOncology
2006English

A Bayesian Dose Finding Design for Clinical Trials Combining a Cytotoxic Agent With a Molecularly Targeted Agent

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2014English

Correction: Article on the Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II Trials

Clinical Cancer Research
Cancer ResearchOncology
2005English

Prognostic and Predictive Factors Associated With Ipilimumab-Related Adverse Events: A Retrospective Analysis of 11 NCI-sponsored Phase I Clinical Trials

Oncotarget
Oncology
2020English

JS4-2Molecular Targeting Agents and Cardiovascular Adverse Events

Annals of Oncology
MedicineOncologyHematology
2018English

Advances in the Study of Molecularly Targeted Agents to Treat Hepatocellular Carcinoma

Drug discoveries & therapeutics
MedicineToxicologyPharmaceuticsPharmacology
2014English

Inappropriate Grading of Adverse Events in Cancer Clinical Trials—Reply

JAMA Oncology
Cancer ResearchOncology
2019English

Lipoprotein(a) Reductions From PCSK9 Inhibition and Major Adverse Cardiovascular Events: Pooled Analysis of Alirocumab Phase 3 Trials

Atherosclerosis
Cardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy